Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catheter Precision (VTAK) Change in Accured Expenses (2017 - 2025)

Catheter Precision (VTAK) has disclosed Change in Accured Expenses for 9 consecutive years, with $30000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses rose 112.66% to $30000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $66000.0, a 99.01% decrease, with the full-year FY2024 number at -$185000.0, up 6.57% from a year prior.
  • Change in Accured Expenses was $30000.0 for Q3 2025 at Catheter Precision, up from -$91000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $6.9 million in Q4 2023 to a low of -$6.9 million in Q3 2023.
  • A 5-year average of -$50421.1 and a median of $11000.0 in 2022 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: soared 5325.0% in 2021, then tumbled 62772.73% in 2023.
  • Catheter Precision's Change in Accured Expenses stood at $1.5 million in 2021, then skyrocketed by 83.94% to $2.8 million in 2022, then soared by 146.74% to $6.9 million in 2023, then tumbled by 99.26% to $51000.0 in 2024, then crashed by 41.18% to $30000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTAK's Change in Accured Expenses are $30000.0 (Q3 2025), -$91000.0 (Q2 2025), and $76000.0 (Q1 2025).